Synta Pharmaceuticals Corp. (NASDAQ:SNTA)

CAPS Rating: 2 out of 5

A biopharmaceutical company focused on discovering, developing and commercializing small molecule drugs that address severe medical conditions with potential markets, including cancer and chronic inflammatory diseases.

Recs

0
Player Avatar TuffPicks (< 20) Submitted: 9/22/2009 12:17:50 PM : Outperform Start Price: $3.15 SNTA Score: +11.46

wallstreet buy list

Report this Post 1 Comment
Member Avatar ssbb123 (53.25) Submitted: 9/24/2009 9:11:02 AM
Recs: 0

Wall street buy list as of September 2008, A LOT LOT LOT of things have changed since then.

Featured Broker Partners


Advertisement